A Cure In Sight and UT Southwestern Bring the Ocular Melanoma Community Together at Eye Believe in Dallas
Harbour Lab Tour: Attendees stepped inside UT Southwestern's lab to meet the scientists studying ocular melanoma. HEPZATO Demonstration: Drs. Chandrasekaran and Shannon led a closer look at liver-directed treatment for metastatic disease. Expert Medical Program: Sessions covered surveillance, biomarkers, adjuvant therapy, treatment sequencing, and emerging therapies. Patient & Caregiver Support: Programming addressed mental health, caregiving, insurance, advocacy, and [...]
Record-Breaking 513 Participants Raise More Than $25,000 at the Palo Alto Lookin’ for a Cure 5K
Researchers identified BAP1 gene abnormalities as a strong predictor of metastatic uveal melanoma. Combining BAP1 changes with chromosome 1 alterations improved the accuracy of metastasis risk prediction. The new classification system successfully separated patients into four distinct metastatic risk groups. Genetic changes linked to uveal melanoma may begin 30–40 years before diagnosis, providing new insight into how the [...]
FDA-Approved Liver-Directed Therapy Shows Consistent Benefit in Metastatic Uveal Melanoma: Review of Delcath’s Phase 3 FOCUS Subgroup Analyses
Read full article: Delcath Systems, Inc. recently announced the publication of important subgroup analyses from its Phase 3 FOCUS study evaluating melphalan delivered via a Hepatic Delivery System in patients with unresectable metastatic uveal melanoma (mUM). Published in the Journal of Cancer Research and Clinical Oncology, the article provides deeper insight into which patient populations may [...]
Metastatic Uveal Melanoma Surveillance: Expert Consensus Brings Clarity to a Critical Gap
Read full article: Metastatic uveal melanoma remains one of the most serious challenges facing patients diagnosed with this rare but aggressive eye cancer. While local control of the primary tumor is often successful, up to 50% of patients will eventually develop metastatic disease—most commonly in the liver. Until recently, however, there has been no standardized, evidence-based [...]
ACIS Announces 2026 “Swing for Sight” Charity Event in Wine Country to Support Ocular Melanoma Research
Read full article: Napa, California – November 1, 2025– The nonprofit organization A Cure In Sight™ (ACIS) is proud to announce the 2026 Swing for Sight fundraiser, to take place at Silverado Resort & Spa, 1600 Atlas Peak Road, Napa, California. All proceeds from the event will directly support critical research and patient services for ocular melanoma. [...]
Imiquimod Shows Promise as a Topical Treatment for Ocular Melanoma–Related Surface Cancers
Read full article: Advances in topical immunotherapy are opening new possibilities for managing rare and challenging eye cancers, including ocular melanoma–related conditions. A recently published case series explores the use of compounded imiquimod 5% ointment as a potential treatment for diffuse conjunctival melanoma in situ (MIS) and ocular surface squamous neoplasia (OSSN)—two ocular surface malignancies with [...]
Julie Frampton to join ACIS’s growing team February 14
Raleigh, Nc., February 17, 2022—A Cure in Sight Ocular Melanoma, today announced that they have expanded their Non-Profit foundation by hiring a Director of Communications. Julie Frampton has joined that role. Julie will be the point of contact across multiple communication avenues.
Frampton has spent the last decade advocating for cancer patients and fundraising to find a cure for Melanoma, of which she is a patient. Her dedication and commitment to those in the cancer world makes her an asset in her new role. She brings with her a knowledge of communication skills and public relations that will further the mission of ACIS.
ACIS and OMF announce webinar collaboration with TriSalus Life Sciences
TriSalus Life Science to review enrolling PERIO-01 clinical trial for those with uveal melanoma with liver metastases
FOR IMMEDIATE RELEASE Contact: Julie Frampton, ACIS
Phone: 254-338-4585
Email: julie@acureinsight.org
ACIS and OMF announce webinar collaboration with TriSalus Life Sciences
TriSalus Life Science to review enrolling PERIO-01 clinical trial for those with uveal melanoma with liver metastases
Raleigh, N.C., April 3, 2022—A Cure in Sight Ocular Melanoma and the Ocular Melanoma Foundation today announced their collaboration with TriSalus Life Sciences® to host a webinar discussing the PERIO-01 clinical trial for adults with uveal melanoma with liver metastases. This webinar, which will take place on April 7, 2022, from 12-1pm ET, will also be presented in English and translated into French, Dutch, and Spanish. To register for the webinar, visit www.tinyurl.com/acistrisalus.
In this webinar, Steven C. Katz, MD, FACS, Chief Medical Officer at TriSalus Life Sciences, will lead a review of the Pressure-Enabled Regional Immuno-Oncology (PERIO-01) clinical trial for adults with uveal melanoma with liver metastases. Dr. Katz will provide insights into barriers to immunotherapy success for this disease. He will be joined by Richard D. Carvajal, MD, Associate Professor of Medicine, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Irving Medical Center, and Joshua Weintraub, MD, Executive Vice Chair of the Department of Radiology at Columbia University.
The PERIO-01 clinical trial is studying an investigational drug, SD-101, delivered intravascularly by the TriNav® Infusion System using the Pressure-Enabled Drug DeliveryTM (PEDDTM) method of administration. The study is evaluating if this platform approach can improve the performance of systemic checkpoint inhibitors in treating patients with liver metastases associated with uveal melanoma by overcoming two major challenges of treatment: immune response suppression and ineffective drug delivery. For more information on the PERIO-01 clinical trial, visit www.periotrial.com.
Webinar Presenters are as follows:
Dr. Katz is the Chief Medical Officer of TriSalus Life Sciences, an immunotherapy company on a mission to extend and improve the lives of patients living with liver and pancreatic tumors. He maintains a part-time role as a surgical oncologist with Brown Surgical Associates. Dr. Katz attended the New York University School of Medicine, receiving the Alpha Omega Alpha Award for graduating with the top academic average in his class. He then completed his general surgery residency at the New York University Medical Center. Dr. Katz completed Fellowships in Immunology and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow.
He maintains a clinical practice focused on liver tumors, pancreas cancer, sarcoma, and melanoma. His laboratory research endeavors focus on immunotherapy for liver metastases and sarcoma. He has served as the principal investigator for five solid tumor CAR-T trials, including four for liver metastases and one for peritoneal carcinomatosis. Dr. Katz has received research grants from numerous societies and the NIH and DOD, in addition to multiple industry partners. He has spent nearly two decades studying how to treat liver immune dysfunction to enable immunotherapy in cancer patients with unmet medical needs.
Dr. Katz is a reviewer for numerous scientific and clinical journals and serves on the editorial boards for Oncogene and Cancer Gene Therapy. His overarching career goal is to develop novel immunotherapy treatments for presently incurable liver and pancreas tumors.
Richard D. Carvajal, MD, Associate Professor of Medicine, Director, Experimental Therapeutics, Director, Melanoma Service, Columbia University Irving Medical Center; Investigator, PERIO-01 Clinical Trial
Dr. Carvajal is an Associate Professor of Medicine, Director of Experimental Therapeutics, and Director of the Melanoma Service at Columbia University Irving Medical Center. His melanoma research has included the study and treatment of uncommon clinical and molecular subsets of melanoma such as those arising from the eye (uveal), from the mucosal surfaces of the body (mucosal), and from the palms of the hands, soles of the feet, or under the fingernails (acral).
His research has received support from the National Cancer Institute, the Food and Drug Administration, the Conquer Cancer Foundation, the Melanoma Research Alliance, the Melanoma Research Foundation, and the Empire Clinical Research Investigator Program. He has authored or coauthored more than 50 peer-reviewed manuscripts, books, and book chapters. His work is focused on the development of novel therapies for melanoma and other cancers, with the overall objective of controlling and curing these diseases.
Joshua L. Weintraub, MD, Executive Vice Chairman, Department of Radiology, Chief, Division of Vascular and Interventional Radiology, Columbia University Irving Medical Center
Dr. Weintraub is the executive vice chairman of the Department of Radiology and chief of the Division of Vascular and Interventional Radiology at Columbia University Irving Medical Center. Board-certified in diagnostic radiology with additional subspecialty certification in vascular and interventional radiology, Dr. Weintraub is professor of radiology (in surgery) at Columbia University Irving Medical Center and an assistant attending radiologist at NewYork -Presbyterian Hospital. He was previously the vice chairman of radiology and director of vascular and interventional radiology at Mount Sinai Medical Center.
Dr. Weintraub is internationally recognized in the field of vascular and interventional radiology as a researcher, educator, and innovator. Dr. Weintraub has participated in multiple clinical trials in the areas of locoregional cancer therapy and vascular disease. He was a co-principal investigator of a major international study evaluating the treatment of acute venous thrombosis via thrombus removal with adjunctive catheter-directed thrombolysis.
Dr. Weintraub is a fellow with the Society of Interventional Radiology and a member of the Radiology Society of North America (RSNA), the American Roentgen Ray Society, and the American College of Radiology (ACR).
A Cure in Sight (ACIS) is a non-profit foundation for ocular melanoma. Founded in 2013 by Melody Burchett, their focus is to provide patient support for those effected with and their families with ocular melanoma, and to raise funds for research. They are members of the Melanoma Action Coalition and Society for Nonprofits. They are sponsored by CASTLE BIOSCIENCES, North Carolina Center for Nonprofits and NORD. The Ocular Melanoma Foundation (OMF) was founded in 2003 by Dr. Robert C. Allen and his son Grant Allen. OMF raises funds, engages academicians and clinicians and are actively partnering with foundations and other leading agencies supporting cancer research.
###
©2022 TriSalus Life Sciences®. All rights reserved. MKT-0386-R01
